Breaking News Instant updates and real-time market news.

MDT

Medtronic

$84.41

-1.76 (-2.04%)

, STJ

Acquired by ABT

$78.35

-2.935 (-3.61%)

11:48
10/11/16
10/11
11:48
10/11/16
11:48

Medtronic evaluating St. Jude investigation, had similar reports, Bloomberg says

Medtronic (MDT) has had reports of lithium clusters like St. Jude (STJ), but said it uses a different battery, according to Bloomberg. Medtronic said it is evaluating the investigation of cardiac devices being conducted by St. Jude, Bloomberg added.

MDT

Medtronic

$84.41

-1.76 (-2.04%)

STJ

Acquired by ABT

$78.35

-2.935 (-3.61%)

  • 19

    Oct

  • 26

    Oct

  • 10

    Nov

MDT Medtronic
$84.41

-1.76 (-2.04%)

08/26/16
PIPR
08/26/16
NO CHANGE
PIPR
Medtronic guidance conservative, says Piper Jaffray
After Medtronic reported higher than expected Q1 EPS and in-line revenue, Piper Jaffray analyst Brooks West says the quarter was "just fine." He says that the company's failure to raise its revenue guidance to reflect recent acquisitions was conservative and "de-risks" its now "beatable" guidance. West expects new products to bolster the company's revenue, and he predicts that it will continue to gain share in CRM. He keeps a $104 price target and Overweight rating on the stock.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/05/16
WEDB
10/05/16
NO CHANGE
WEDB
Outperform
Medtronic CGM adoption could be tempered by false alarm rates, says Wedbush
Wedbush analyst Tao Levy analyzed the recently released Summary and Effectiveness Data for Medtronic's (MDT) 670G System, which he does not believe many outside of the Continuous glucose monitoring, or CGM, manufacturers have read, and came away with the belief that its new Guardian Sensor CGM standalone system suffers from a relatively large rate of false hypoglycemia alarms. While it cannot be known for sure how competitive the Guardian Sensor will be when it is eventually approved and launched in the next several months, Levy thinks elevated false alarm rates could temper adoption and that it is "too early to assume" that the product will hinder Dexcom's (DXCM) growth. The analyst keeps a Neutral rating on Medtronic and an Outperform rating on Dexcom.
STJ Acquired by ABT
$78.35

-2.935 (-3.61%)

08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

RIG

Transocean

$11.47

-0.73 (-5.98%)

18:27
01/16/18
01/16
18:27
01/16/18
18:27
Hot Stocks
Transocean shareholders show 'overwhelming support' for Songa transaction »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

WMT

Walmart

$100.69

-0.18 (-0.18%)

18:13
01/16/18
01/16
18:13
01/16/18
18:13
Periodicals
Wal-Mart COO to be named international CEO, Reuters says »

Wal-Mart Stores COO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CME

CME Group

$152.20

-0.53 (-0.35%)

18:05
01/16/18
01/16
18:05
01/16/18
18:05
Hot Stocks
CME reaches daily trading volume record for Henry Hub Nat Gas futures on Jan 12 »

CME Group announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 01

    Feb

CE

Celanese

$109.67

-1.67 (-1.50%)

18:02
01/16/18
01/16
18:02
01/16/18
18:02
Hot Stocks
Celanese announces price increases for engineered materials polymer products »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SRC

Spirit Realty

$8.07

-0.03 (-0.37%)

17:46
01/16/18
01/16
17:46
01/16/18
17:46
Hot Stocks
Spirit Realty funds $35M into Shopko master lease »

Spirit Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

17:45
01/16/18
01/16
17:45
01/16/18
17:45
Conference/Events
Nutanix management to meet with Piper Jaffray »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

17:41
01/16/18
01/16
17:41
01/16/18
17:41
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Juno Therapeutics…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

NEWA

Newater Technology

$15.80

2.8 (21.54%)

VRS

Verso

$17.00

0.06 (0.35%)

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

IPSEY

Ipsen

RNST

Renasant

$43.86

0.15 (0.34%)

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

CSX

CSX

$58.13

-1.12 (-1.89%)

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

HIVE

Aerohive

$5.70

-0.19 (-3.23%)

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

XON

Intrexon

$13.77

-0.94 (-6.39%)

BOOT

Boot Barn

$19.10

-0.15 (-0.78%)

F

Ford

$13.10

-0.13 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 26

    Feb

  • 01

    Mar

  • 25

    Mar

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

NRZ

New Residential

$17.63

-0.11 (-0.62%)

17:35
01/16/18
01/16
17:35
01/16/18
17:35
Earnings
Breaking Earnings news story on New Residential »

New Residential sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

17:30
01/16/18
01/16
17:30
01/16/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Exelixis »

Exelixis up 3.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

17:30
01/16/18
01/16
17:30
01/16/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Exelixis 

Exelixis trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

17:27
01/16/18
01/16
17:27
01/16/18
17:27
Periodicals
Celgene in discussions to acquire Juno Therapeutics, WSJ reports »

Celgene (CELG) is in…

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

17:25
01/16/18
01/16
17:25
01/16/18
17:25
Conference/Events
CFA Society of New York to hold a discussion »

The CFA Society of New…

YUMA

Yuma Energy

$1.49

-0.14 (-8.59%)

17:21
01/16/18
01/16
17:21
01/16/18
17:21
Syndicate
Breaking Syndicate news story on Yuma Energy »

Yuma Energy files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$67.85

-0.7 (-1.02%)

17:18
01/16/18
01/16
17:18
01/16/18
17:18
Earnings
Pinnacle Financial reports Q4 adjusted EPS 97c, consensus 94c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRZO

Carrizo Oil & Gas

$23.26

-1.07 (-4.40%)

17:16
01/16/18
01/16
17:16
01/16/18
17:16
Syndicate
Carrizo Oil & Gas 1.2M share Block Trade; price range $23.00-$23.15 »

Citi is acting as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

IAG

IAMGold

$6.11

0.03 (0.49%)

17:13
01/16/18
01/16
17:13
01/16/18
17:13
Hot Stocks
IAMGold sees 2018 gold production between 850K and 900K ozs »

IAMGOLD announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BAESY

BAE Systems

$33.20

0.285 (0.87%)

, GD

General Dynamics

$206.33

-4.26 (-2.02%)

17:10
01/16/18
01/16
17:10
01/16/18
17:10
Hot Stocks
BAE Systems and General Dynamics awarded $158M U.S. Navy contract option »

BAE Systems (BAESY) and…

BAESY

BAE Systems

$33.20

0.285 (0.87%)

GD

General Dynamics

$206.33

-4.26 (-2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

URG

UR-Energy

$0.71

-0.032 (-4.30%)

, UUUU

Energy Fuels

$1.66

-0.15 (-8.29%)

17:10
01/16/18
01/16
17:10
01/16/18
17:10
Hot Stocks
UR-Energy and Energy Fuels submit petition to DOC »

Ur-Energy (URG) and…

URG

UR-Energy

$0.71

-0.032 (-4.30%)

UUUU

Energy Fuels

$1.66

-0.15 (-8.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

UUUU

Energy Fuels

$1.66

-0.15 (-8.29%)

, URG

UR-Energy

$0.71

-0.032 (-4.30%)

17:09
01/16/18
01/16
17:09
01/16/18
17:09
Hot Stocks
Energy Fuels, Ur-Energy file petition with DOC over effects of uranium imports »

Energy Fuels (UUUU) and…

UUUU

Energy Fuels

$1.66

-0.15 (-8.29%)

URG

UR-Energy

$0.71

-0.032 (-4.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

FAST

Fastenal

$55.44

-0.15 (-0.27%)

17:08
01/16/18
01/16
17:08
01/16/18
17:08
Hot Stocks
Fastenal raises quarterly dividend to 37c from 32c »

Fastenal reported its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EGO

Eldorado Gold

$1.35

0.06 (4.65%)

17:07
01/16/18
01/16
17:07
01/16/18
17:07
Hot Stocks
Eldorado Gold sees FY18 gold production 160,000-190,000 ounces »

Sees FY18 development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGO

Eldorado Gold

$1.35

0.06 (4.65%)

17:06
01/16/18
01/16
17:06
01/16/18
17:06
Hot Stocks
Eldorado Gold reports FY17 gold production 285,919 ounces »

Says FY17 revised gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

, IPSEY

Ipsen

17:06
01/16/18
01/16
17:06
01/16/18
17:06
Hot Stocks
Exelixis and Ipsen disclose Phase 3 results of Cabozantinib »

Exelixis (EXEL) and Ipsen…

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

IPSEY

Ipsen

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

ABX

Barrick Gold

$15.20

0.08 (0.53%)

17:05
01/16/18
01/16
17:05
01/16/18
17:05
Hot Stocks
Barrick Gold reports preliminary FY17 gold production of 5.32M ounces »

Barrick Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 22

    Feb

GRA

W.R. Grace

$72.93

-0.63 (-0.86%)

17:05
01/16/18
01/16
17:05
01/16/18
17:05
Hot Stocks
W.R. Grace signs $200M agreement with two Kazakhstan operators »

W. R. Grace & Co. has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.